Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Publication Date: 2024 Aug 22
Full Text Sources
Authors
Toni K Choueiri; Thomas Powles; Katriina Peltola; Guillermo de Velasco; Mauricio Burotto; Cristina Suarez; Pooja Ghatalia; Roberto Iacovelli; Elaine T Lam; Elena Verzoni; Mahmut Gümüş; Walter M Stadler; Christian Kollmannsberger; Bohuslav Melichar; Balaji Venugopal; Marine Gross-Goupil; Alexandr Poprach; Maria De Santis; Fabio A Schutz; Se Hoon Park; Dmitry A Nosov; Camillo Porta; Jae Lyun Lee; Xavier Garcia-Del-Muro; Elisa Biscaldi; Ray Manneh Kopp; Mototsugu Oya; Li He; Aobo Wang; Rodolfo F Perini; Donna Vickery; Laurence Albiges; Brian RiniAbstract
OBJECTIVE
Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies.
Source
The New England journal of medicine
Pub Types(s)
Journal Article
Language
English
PubMed ID
39167807